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number of research teams existed. This was even more 
surprising, knowing that Germany looks back to a fan-
tastic tradition of excellent AD research. Needless to say, 
that it all started in Germany, when Alois Alzheimer de-
scribed for the first time the brain pathology of a heavily 
demented patient exactly 100 years ago (November 1906). 
Furthermore, Germany is also the place where the   -am-
yloid precursor protein (  APP) gene was cloned. This 
major breakthrough was possible due to the pioneering 
work of Konrad Beyreuther, who is now regarded as the 
father of modern AD research. A number of the members 
of this network are his ‘children’ or ‘grandchildren’.
 The idea behind our initiative was to bring together 
molecular biologists working in AD research from com-
plementary fields and opinions and to provide a novel 
platform for collaborations. In addition, interdisciplinary 
collaborations should be initiated by including cell biolo-
gists. Finally, we wanted to create an opportunity for 
young investigators to start their own and independent 
research. 
 The DFG-sponsored priority program represents an 
optimal opportunity to support such collaborative na-
tionwide research on novel ideas, which allows all inter-
ested scientists throughout the country to work in the 
field and to benefit from a collaborative network. The 
program runs for 6 years, with international reviews at 
the beginning and after every other year.
 This special issue of  Neurodegenerative Diseases is de-
voted to a 6-year program of the Deutsche Forschungsge-
meinschaft (DFG), which supported up to 13 projects on 
cellular mechanisms of Alzheimer’s disease (AD) with 7.5 
million euros. Since the maximum funding by the DFG 
for such initiatives is 6 years, the program came to an end 
in June 2006. The members of this program have used 
this occasion to present their projects, their major find-
ings and the collaborative network in the form of sum-
marizing articles.
 At the International Conference on Alzheimer’s Dis-
ease in Amsterdam in 1998, Volker Herzog (University of 
Bonn) and C. Haass discussed for the first time the idea 
to initiate a nationwide priority program on AD research 
with a special focus on cellular mechanisms leading to 
amyloid-  (A  ) peptide production and tau aggregation. 
We both felt that this was about time, since a collabora-
tive research program on this hot topic did not exist in 
Germany. For us this was quite surprising, since we were 
used for many years to run collaborative projects with 
scientists throughout Europe and the United States. 
Moreover, we had the strong feeling that by this time 
 Germany’s AD researchers were split into two opposing 
groups, the ‘Baptists’ and the ‘Tauists’. This dogmatic 
separation of the field prevented coordinated and collab-
orative research for decades in Germany.  Moreover, we 
also found it surprising that in Germany only a small 
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 Fig. 1. Alzheimer laboratories of the Priority Program SPP 1085 
in Germany (only members of the last funding period are shown). 
Newly and previously established laboratories are in red and 
green, respectively. 
 Fig. 2. The 6th Eibsee Meeting. 
 Fig. 3. Impressions from the Eibsee V and VI conferences.  A Left 
to right: Eckhard Mandelkow (MPI, Hamburg), Raymond Kelle-
her (MIT), Rudi Tanzi (MGH and Harvard Medical School), To-
bias Hartmann (Center for Molecular Biology Heidelberg), Dora 
Kovacs (MGH and Harvard Medical School), Jee Shen (Harvard 
Medical School), and Eva Maria Mandelkow (MPI Hamburg). 
 B Peter St. George-Hyslop (University of Toronto).  C Christoph 
Hock (University of Zürich). D Charles Glabe (University of Cal-
ifornia, Irvine).  E Frank LaFerla (University of California, Ir-
vine).  F Michael Shelanski (Columbia University).  G Gang Yu 
(University of Texas).  H Zugspitze, Eibsee, and the lake at sunrise. 
 I Fred van Leuven (University of Leuven).  J Peter Kloetzel (Cha-
rite, Berlin) and (right) Gerd Multhaup (Free University Berlin). 
 K Peter Breuer announcing the first Award of the Hans and Ilse 
Breuer Foundation.  L Harald Steiner (Ludwig Maximilians Uni-
versity Munich) receiving the Hans and Ilse Breuer Award for 
Alzheimer’s Disease Research.  M Dietrich Reinhardt (Dean of the 
Medical Faculty of the Ludwigs Maximilian University of Mu-
nich) holding the laudatio on Harald Steiner.  1 
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 After a first and very successful review, the program 
started under the name ‘Priority Program SPP1085 Cel-
lular Mechanisms of Alzheimer’s Disease’ in spring 1999. 
We covered many aspects of modern AD research cen-
tered around the cell biology of APP, the three different 
secretase activities and tau. These included in vivo analy-
sis of APP transport, functional analysis of presenilin, 
identification and reconstitution of   -secretase, assembly 
of the   -secretase complex, identification of novel   -
secretase substrates,   -secretase function in animal mod-
els  (Caenorhabditis elegans and  Drosophila) , cellular 
analysis of   -secretase complex components, life imaging 
of   -secretase trafficking, identification of   -secretase-
like proteases, functional analysis of APP and its homo-
logues in mice and primary neurons, effects of choles-
terol on A  peptide generation, functional analysis of 
BACE and its dimerization, phosphorylation of secre-
tases, the role of   -secretase in the prevention of A  pro-
duction, tau aggregation, and effects of abnormally phos-
phorylated tau on cellular transport. In addition, projects 
related to novel therapeutic strategies based on the cel-
lular and molecular mechanisms discovered in our pro-
gram were initiated. Drugs were screened for their poten-
tial to block tau aggregation and its detrimental effects on 
cellular transport,   -secretase modulators were investi-
gated for their potential to selectively inhibit A  peptide 
generation without affecting Notch signaling, and novel 
compounds were designed to block and investigate secre-
tase activities. The outcome of these projects will be sum-
marized by the members of the SPP1085 in their articles 
in this special issue of  Neurodegenerative Diseases . In ad-
dition, a list of publications originating from the SPP1085 
projects can be found below. By going through these ar-
ticles one can immediately appreciate that AD research 
in Germany grew together to a group of internationally 
competitive scientists. Tauists are now even working with 
Baptists! Moreover, we established a growing number of 
novel research teams led by young investigators (Drs. 
Weggen, Kaether, Lichtenthaler, Kins, and Steiner). Fur-
thermore, several members of the SPP1085 obtained ma-
jor positions at German Universities (Drs. Baumeister, 
Hartmann, Pietrzik, Schmidt, Multhaup, Walter, Müller, 
and Haass), and laboratories focusing on AD are now dis-
tributed throughout Germany ( fig. 1 ). 
 Besides funding the research projects, the DFG also 
supported annual meetings to allow discussion and ex-
change of data. All members and their co-workers, the 
reviewers, and selected speakers from all over the world 
were invited to these meetings. The meetings took place 
at a rather remote place in the Bavarian Alps and are now 
known as the Eibsee Meetings. Six such meetings were 
held throughout the funding period including satellite 
meetings of the project leaders in Hamburg and Berlin 
where the co-speaker of the SPP has accepted the chair 
for biochemistry during the funding period (G. Mult-
haup, Free University of Berlin). These conferences 
turned out to be an excellent platform for generating new 
collaborations and for bringing together German AD re-
searchers. This meeting developed to an internationally 
well-recognized conference. Importantly, the very special 
‘Eibsee atmosphere’ allowed detailed informal discussion 
during hiking and at the fireplace in the evening ( fig. 2 , 
 3 ). Here, many novel ideas and collaborations developed, 
frequently with inclusion and advice of our international 
guest speakers and reviewers. The Eibsee Meeting is now 
the German platform for AD research. We are extremely 
excited that the Hans and Ilse Breuer Foundation will 
generously support this meeting in the future. At this 
year’s Eibsee VI conference (the last meeting sponsored 
by the DFG), the foundation already invited Dr. Dennis 
Selkoe as a keynote speaker. Moreover, the Hans and Ilse 
Breuer Foundation will not only help to keep German AD 
researchers together by supporting the Eibsee confer-
ence, but will also directly support AD research in Ger-
many by offering a major research award (EUR 100,000) 
and several stipends for PhD students. It is our great plea-
sure to congratulate Dr. Harald Steiner as the first recip-
ient of this award.
 Finally, we want to thank the DFG (Drs. Golla and 
Schmidtmann) for the strong support throughout these 
years. We also greatly acknowledge the tremendous work 
and important scientific advice from the international 
board of reviewers (Drs. St. George-Hyslop, Glabe, Hepp-
ner, Kloetzel, van Leuven, Saftig, and Aguzzi). Many of 
them not only had to review numerous applications but 
also travel long distances for the final board meetings and 
our conferences.  
 We are looking forward to fruitful and long-lasting 
excellent AD research in Germany based on this success-
ful DFG program!
 
